The pattern of new-onset AF differed between ranolazine vs. placebo : clinically insignificant AF ( five patients in ranolazine vs. seven in placebo ) , paroxysmal AF ( @ vs. @ patients ) , and predominantly chronic AF ( @ vs. @ patients , three-way P < @ ) .